Illumina Announces Bold Steps to Accelerate the Adoption of Individual Genome Sequencing.
BOSTON -- Illumina, Inc. (NASDAQ:ILMN) today announced a series of measures to increase access to genetic information by individuals and physicians who participate in the company's Individual Genome Sequencing (IGS) service. In his remarks at the 3rd annual Consumer Genetics Show in Boston, Illumina President and CEO Jay Flatley announced a significant price reduction for its individual genome sequencing service from $19,500 to $9,500. Additionally, the Company is offering a program to subsidize sequencing for patients with life-threatening disease where whole-genome sequence information may provide their physician with critical tools for diagnosis or treatment. The price under this program is $7,500 per genome and, for cancer patients, $10,000 for a tumor-normal pair.
Painting a view of how individuals ultimately will manage their genetic data, the Company demonstrated the "MiGenome" iPad application, which puts genomic information at the individual's fingertips. This application allows an individual to visualize their genome and interrogate it for mendelian disorders, disease risk and pharmacogenomic drug response.
"The advances we've made with our sequencing platform have enabled us to offer breakthrough pricing for whole human genome sequencing," said Mr. Flatley. "By making sequencing more affordable and developing tools like our new 'MiGenome' iPad application, we believe that we can significantly accelerate the adoption of individual genome sequencing which will, in turn, pave the way to a future where an individual's genome sequence informs and personalizes his healthcare."
For more information about the Illumina Individual Genome Sequencing service, please visit www.everygenome.com/cgc.
Illumina (http://www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
This release contains forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 8, 2011|
|Previous Article:||Fitch: Tobacco Regulatory and Litigation Risks are Manageable.|
|Next Article:||Fitch Rates Kissimmee Utility Authority, (FL's) 2011 Revs 'AA-'; Outlook Stable.|